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Carboxypeptidase 03 from Pseudomonas sp. M・27hydrolyzed predominately N-acyl glutamic 
acid. We found that carboxypeptidase 03， capable of liberating the carboxyl-terminal gluta-
mate from folic acid analogue， showed in vitro antitumor activities against human carcinoma 
KB and PC-3 cells among ten kinds of human carcinoma cell lines. It can be expected to 
be useful as an anticancer agent against limited cell lines. 
Introduction 
In 1948， Ferber et al. 1) demonstrated the in・
duction of brief remissions in children with acute 
leukemia using the folate analogue aminopterin. 
Since then， methotrexate has been widely used as 
a folic acid antagonist in the chemotherapy of 
cancer， notably leukemias and choriocarcinoma. Its 
therapeutic action is based on inhibition of di-
hydrofolate reductase. However， resistance to 
methotrexate has been associated with increased 
levels of the target enzyme， dihydrofolate reductase， 
and with impaired cellular uptake of the drug. 
In a search for new antifolate chemotherapeutic 
agents， several enzymes which hydrolyze the pep-
tide linkage of the C-terminal glutamate residue of 
folic acid， carboxypeptidase 0，2) 013) and 024) 
have been found. The action of folic acid-de-
grading enzyme led to investigation of its useful-
ness as an antineoplastic agent， and its antitumor 
activity was demonstrated -against several murine 
tumors in vitro5) and in vivo.。
Previously during purification of polymyxin ac-
ylase from Pseudomonas sp. M・27strain which 
produces it， we found a new enzyme， carbox-
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ypeptidase 03， that hydrolyzed only N-fatty acyl 
glutamic acid or aspartic acid， but not polymyxins.7) 
The enzyme resembles carboxypeptidase 01 or O2 
in its glutamate-releasing activity. However， itacts 
not only on the L-from but also on the D-form of 
acidic amino acids and shows affinity for the 
long-chain fatty acyl group but not the benzoyl 
group. In this paper， we describe the in vitro 
antitumor activity of carboxypeptidase 03 against 
murine and human tumor cels and its substrate 
specificity for folic acid and its analogues. 
Materials and Methods 
Preparation of carboxypeptidase G3 
Carboxypeptidase 03 was purified to homogeneity 
from an acetone輔driedcel powder of Pseudomonas 
sp. M-27 by the procedure described in our 
preceding paper. 7) This enzyme had a single peak 
with a molecular weight of 60，000 on a calibrated 
Superdex column and consisted of four subunits of 
identical molecular weights (Mr:15， 000). Its iso-
electric point was estimated to be 7. 2. The enzyme 
hydrolyzed predominately acidic peptides and N-
acyl amino acids with glutamic acid or aspartic 
acid in the C-terminus. The observed Vmax and 
Km for N-octanoyl・DL-glutamic acid were 





enzyme was not strongly affected by thiol enzyme 
inhibitors (p・chloromercuribenzoate，iodoacetic acid) 
or serine protease inhibitors (diisopropylphosphoro 
fluoridate， phenylmethane sulfonylfluoride)， but 
was inhibited by metal chelators. 
Enzyme assay Carboxypeptidase or acyl amino 
acid acylase activity was assayed from the nin-
hydrin color spot of liberated amino acid on the 
TLC plate as follows: the reaction mixture (10μ1) 
containing 1μmol of folic acid and its analogue， 
lmM ZnClz and the enzyme solution (25μ1) in 
20mM Tris buffer (pH8.0) was incubated at 370C 
for several hours. An 1・μ1portion of the reaction 
mixture was developed by TLC on a silica gel 
plate Csolvent system upper layer of n・BuOH-
AcOH-H20 (4:1:3) containing 1/20 pyridine by 
volumeJ. The amount of amino acid liberated was 
measured by the ninhydrin method with Chro-
moscan 200/201 (Joyce-Loebl， England). During 
enzyme purification， this assay method using N二
octanoyl-DL-glutamic acid was used. The amount 
of liberated amino acid in the mixture was mea-
sured colorimetrically by the ninhydrin method. 
In vitro antitumor activity of carboxypeptidase G3 
The terazolium幽basedsemiautomated colorimetric 
assay (MTT assay) developed by Carmichael et 
al.8) was modified and used for the in vitro assay. 
Briefly， 2000 cels in 180μ1 of RPMI-1640 medium 
(Nissui Pharmaceutical Co.， Osaka， Japan) sup-
plemented with 10同 heat-inactivatedfetal bovine 
serum (Gibco Lab.， Grand Island， NY， USA)， 
penicillin G (100 units/ml) and streptomycin 
(100μg/ml) were seeded in a 96-well flat bottom 
microtest plate (InterMed， Roskilde， Denmark) 
and 20μ1 each of drug solutions of graded con-
centrations was simultaneously added to each well 
triplicate samples. The plate was incubated for 3 d 
at 370C in a humidified atmosphere of 5町CO2・
MTT reagent [3・(4，5-dimethylthiazol-2・yl)-2， 
5-diphenyltetrazolium bromideJ (sigma Chemical 
Co.， St Louis， MO. USA) was prepared at a 
concentration of 2mg/ml in Dulbecco's phosphate 
buffered saline without ca1cium and magnesium 
and strored in a refrigerator. On the third day， 
MTT reagent (25μ1) was added to each well. 
After another 4-h incubation at 370C， the 
microplate was centrifuged at 1500 rpm for 10 min 
and the medium was removed by aspiration. To 
solubilize the resulting MTT-formazan， 0.2ml of 
dimethylsulfoxide was added to each well followed 
thorough mixing with a mechanical plate mixer. 
Absorbance at 540 nm (OD540) was measured with 
an ImmunoReader NJ・2000 (InterMed Japan， 
Tokyo， Japan). The percentage of cel1 growth 
inhibition was ca1culated by the following formula 
070 of cel growth inhibition (1-T/C) x 100， 
where C is the mean OD540 of the control group 
and T is that of the treated group. ICso value was 
derermined graphically from the dose-response 
curve with at least 3 drug concentration points. 
Results and Discussion 
Table 1 shows the activity of carboxypeptidase 
G3 for folic acid and its analogues. Folic acid was 
exclusively hydrolyzed by this enzyme， but for 
methotrexate the glutamate-releasing activity was 
very weak as compared with those of carbox-
ypeptidase G1 (725μmol/min/mg) and G2 
(215μmol/min/mg). To investigate the antitumor 
activity of carboxypeptidase G3， murine leukemia 
cels and a variety of human neoplastic cels were 
used. As shown in Table 2， appreciable antitumor 
effects were observed for human carcinoma KB 
and PC-3 cels specifically， but the other cels were 
very slightly affected. 
Earlier， in a search for new antifolate 
chemotherapeutic agents， McCullough and 
Chabner3，9) isolated and purified an enzyme from 
Pseudomonas stutzeri， carboxypeptidase G1， which 
hydrolyzed the peptide linkage of the C-terminal 
glutamate residue of folic acid analogue. They 
observed that carboxypeptidase G1 inhibited the 
growth of L5178Y and L1210 murine leukemia and 
indicated that the antineoplastic activity was a 
consequence of folic acid depletion.5，6) Chabner et 
al. 10) reported that carboxypeptidase G1 has no 
selective inhibitory effect on thymidylate synthesis， 
as does methotrexate， but probably depresses DNA 
synthesis through its effects on purine synthesis or 
amino acid metabolism. Valerino et al.lI) reported 
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The enzymatic reaction conditions are described in the text. 
Table 2. Inhibitory Effects of Carboxypeptidase G3 on the Growth of Various Murine and Hunian Tumor Cell 
Lines in vitro. 
Cellline Origin ICso(μg/ml) 
L5178Y Murine leukemia >25 
KB Human epidermoid carcinoma 15 
NPC-TY861 Human epipharynx squamous carcinoma >25 
PC-3 Human lung adenocarcinoma 7.4 
PC-8 Human lung adenocarcinoma >25 
PC-13 Human lung large-cell carcinoma >25 
QGδ6 Human lung squamous cel carcinoma >25 
KATO-ill Human stomach adenocarcinoma >25 
ST-KM Human stomach adenocarcinoma >25 
NUGC-4 Human stomach adenocarcinoma >25 
OST Human osteosarcoma >25 
that carboxypeptidase G from Pseudomonas can be Walker carcinoma in rats: Carboxypeptidase G3 
used in rescue therapy following high-dose has similar properties such as carboxyl-terminal 
methotrexate regimes， because of its ability to glutamate-releasing activity and requirement of 
hydrolyze the glutamate moiety from methotrexate Zn2ヘbutthe optical specificity of the enzyme is 
to form 4・amino-.N1O-methylpteroate，which is a markedly different from that of the known enzyme， 
much les active inhibitor of dihydrofolate reduc- G， G1 and G2， that is， carboxypeptidase C3 acts 
tase. Sherwood et al.4) found that carboxypepti- not only on the L-form but also on the o-form of 
dase G2 from Peudomonas sp. RS-16 had similar glutamic acid. Carboxypeptidase G3， capable of 
Km values to G1 for folate (4.0μM) and meth- liberating the carboxyl-terminal glutamate from 
otrexate (8.0μM)， but les affinity for leucovorin folic acid analogue， inhibited very slightly the 
(120μM). This may be of significance if the en- growth of muriJ;le leukemia， but showed remark-
勾meis used in rescue resimes together with leu- able antitumor activities against human carcinoma 
covorin in cases where high-dose methotrexate KB and PC・3cels among ten kinds of human 
therapy leads to toxicity. Carboxypeptidase O2 also carcinoma cel lines. The mechanism of the an-
exhibited antitumor activity in its own right against titumor activity of carboxypeptidase G3 seems to 
???
(Yasuda. Shimo' Kimura . Sasaki) 
be based on the degradation of folic acid. Ac-
cordingly， carboxypeptidase G3 can be expected to 
be useful as an anticancer agent against limited cel 
lines， which can regulate the level of folic acid in 
vivo， and be also used in rescue therapy following 
high-dose methotrexate regimes. Thus carboxypep-
tidase G3 is promising as an enhancer of antitumor 
activity when used with other active reagents， and 
also may be of significance for chemotherapy to 
target specific human neoplastic cels， such as KB 
and PC・3.
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